Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 27 EP applications Jochen Carl Beyermann has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 18, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11797306

COMBINATION THERAPY COMPRISING VEMURAFENIB AND AN INTERFERON FOR USE IN THE TREATMENT OF CANCER

IPC classification:
A61P 35/00, A61K 38/21, A61K 31/437
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP12706826

METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR

IPC classification:
A61K 31/55, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12709607

IMIDAZO PYRAZINES

IPC classification:
A61K 31/4985, C07D 487/04, A61P 35/02
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP12801538

PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY FOR HIGH MELTING HYDROPHOBIC COMPOUND

IPC classification:
A61K 47/38, A61K 47/32, A61K 31/506, A61K 31/4745, A61K 31/437, A61K 9/20, A61K 9/14, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP13701434

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1

IPC classification:
A61K 47/48, A61P 35/00, A61P 29/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13701748

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3

IPC classification:
A61K 47/48, A61P 35/00, A61P 29/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP13708466

SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES

IPC classification:
A61K 31/4035, A61K 31/40, C07F 9/572, C07D 493/04, C07D 405/12, C07D 207/16, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
The patent has been granted
EP13709468

COMBINATION THERAPY (VEMRUFENIB AND A MDM2 INHIBITOR) FOR THE TREATMENT PROLIFERATIVE DISORDERS

IPC classification:
A61K 45/06, A61K 31/437, A61K 31/4164, A61K 31/402, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13711004

METHOD FOR ADMINISTRATION OF AN ANTI TUMOR AGENT

IPC classification:
A61K 31/40, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP13725648

SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES

IPC classification:
A61K 31/40, C07D 409/04, C07D 401/06, C07D 207/16
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13753131

COMBINATION THERAPIES FOR MELANOMA COMPRISING ADMINISTERING COBIMETINIB AND VEMURAFINIB

IPC classification:
A61K 31/4523, A61K 31/437, C12Q 1/68, A61P 35/04, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14701504

PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY

IPC classification:
A61K 47/38, A61K 47/36, A61K 47/32, A61K 31/40, A61K 9/16, A61K 9/14, A61K 9/10, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14706535

METHODS OF TREATING CANCER AND PREVENTING DRUG RESISTANCE

IPC classification:
A61K 45/06
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14706519

ASYMMETRIC SYNTHESIS OF A SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDE

IPC classification:
C07D 207/16
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP12700482

NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER

IPC classification:
A61P 35/00, A61K 31/407, A61K 31/4025, A61K 31/402, A61K 31/4015, C07D 471/04, C07D 413/10, C07D 403/10, C07D 403/04, C07D 401/04, C07D 207/50
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11802425

SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS

IPC classification:
A61K 47/18, A61K 31/713, A61K 48/00, C12N 15/11, C12N 15/87
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14731223

COMBINATION OF RO5503781, CAPECITABINE AND OXALIPLANTIN FOR CANCER THERAPY

IPC classification:
A61K 31/7068, A61P 35/00, A61K 31/40, A61K 31/513, A61K 31/555
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14732136

COMBINATION OF RO5503781 AND CAPECITABINE FOR CANCER THERAPY

IPC classification:
A61P 35/00, A61K 31/40, A61K 31/7068
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14732865

STABLE INTRAVENOUS FORMULATION

IPC classification:
A61P 35/00, A61K 31/40, A61K 9/19, A61K 9/08, A61K 47/26, A61K 47/18, A61K 47/02, A61K 9/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14736727

MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP15159611

COMBINATION THERAPY OF ANTIBODIES HUMAN CD40 ACTIVATING ANTIBODIES AND ANTI HUMAN PLD-1 ANTIBODIES

IPC classification:
A61K 39/00, A61P 35/00, A61K 39/395, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
APPLICATION REFUSED
EP11739076

SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS

IPC classification:
C12N 15/87, C07K 7/02, C07C 69/96, C07C 271/20, A61K 47/48, A61K 48/00, A61K 31/7088, A61K 38/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP14808911

NOVEL COMBINATION TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML)

IPC classification:
A61K 31/7068, A61K 31/40, A61K 31/77, A61P 35/02, A61P 35/00, A61K 45/06
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15181188

METHODS FOR PERSONALIZING PATIENT CANCER THERAPY WITH ANTI ANGIOGENIC COMPOUNDS

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
APPLICATION PUBLISHED
EP15714843

SOLID FORMS OF A PHARMACEUTICALLY ACTIVE COMPOUND

IPC classification:
A61P 35/00, A61K 31/40, C07D 207/10
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15748249

COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1

IPC classification:
A61K 39/00, A61P 35/00, A61K 39/395, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15780808

METHODS FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST

IPC classification:
G01N 33/49, G01N 33/574
Applicant:
F. Hoffmann-La Roche AG
Agent:
Jochen Carl Beyermann, F. Hoffmann-La Roche AG
Status:
Request for examination was made

Please Sign in to use this feature